Tolterodine use for symptoms of overactive bladder

Annals of Pharmacotherapy

Volumn 33, Issue 10, 1999, Pages 1073-1082

  Ruscin, J Mark ^a   Morgenstern, Nora E ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

Incontinence; Overactive bladder; Tolterodine

Indexed keywords

5 HYDROXYMETHYLTOLTERODINE; AMIODARONE; ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; CIMETIDINE; CLARITHROMYCIN; CLOMIPRAMINE; CYTOCHROME P448; DD 01; DESIPRAMINE; DIGOXIN; DRUG METABOLITE; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; ITRACONAZOLE; NEUROLEPTIC AGENT; OXYBUTYNIN; PAROXETINE; PNU 200577; PROPAFENONE; QUINIDINE; RITONAVIR; SERTRALINE; THIORIDAZINE; TOLTERODINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; DETRUSOR DYSSYNERGIA; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG HYDROXYLATION; DRUG SAFETY; DRUG STRUCTURE; DYSPEPSIA; FATIGUE; HEADACHE; HEART PALPITATION; HUMAN; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; URINE INCONTINENCE; URODYNAMICS; VERTIGO; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; CLINICAL TRIALS; CRESOLS; HUMANS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; URINARY BLADDER DISEASES; URINARY INCONTINENCE;

EID: 0032884405     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18427     Document Type: Review

References (44)

1. Hampel C, Wienhold D, Benken N, Eggersmann C, Thuroff JW. Definition of overactive bladder and epidemiology of urinary incontinence. Urology 1997;50(suppl 6A):4-14.
2. Fantl JA, Newman DK, Colling J. Urinary incontinence in adults: acute and chronic management. Clinical practice guideline no. 2, March 1996 update. Washington, DC: US Public Health Service, Agency for Health Care Policy and Research, 1996. AHCPR Publication 96-0682.
3. Wyman JF, Harkins S, Choi S, Taylor J, Fantl JA. Psychosocial impact of urinary incontinence in women. Obstet Gynecol 1987;70:378-80.
4. Ekelund P, Rundgren A. Urinary incontinence in the elderly with implications for hospital care consumption and social disability. Arch Gerontol Geriatr 1987;6:11-8.
5. Chutka DS, Fleming KC, Evans MP, Evans JM, Andrews KL. Urinary incontinence in the elderly population. Mayo Clin Proc 1996;71:93-101.
6. Donnellan CA, Fook L, McDonald P, Playfer JR, Oxybutynin and cognitive dysfunction. Br Med J 1997;315:1363-4.
7. Package insert. Detrol (tolterodine). Kalamazoo, MI: Pharmacia & Upjohn Co., March 1998.
8. Ouslander JG. Incontinence. In: Hazzard WR, Bierman EL, Blass JP, Ettinger WH Jr, Halter JB, eds. Principles of geriatric medicine and gerontology. New York: McGraw-Hill, Inc., 1994:1229-49.
9. Eglen RM, Reddy H, Watson N, Challis RAJ. Muscarinic acetylcholine receptor subtypes in smooth muscle. Trends Pharmacol Sci 1994;15: 114-9.
10. Gillberg PG, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol 1998;349:285-92.
11. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 1995;273:959-66.
12. Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997;327:195-207.
13. Lukkari E, Taavitsainen P, Juhakoski A, Pelkonen O. Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes. Pharmacol Toxicol 1998;82:161-6.
14. Nilvebrant L, Gillberg PG, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 1997;81:169-72.
15. Mitchelson F. Muscarinic receptor differentiation. Pharmacol Ther 1988; 37:357-423.
16. Postlind H, Danielson A, Lindgren A, Andersson SH. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochrome P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998;26:289-93.
17. Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther 1998;63:529-39.
18. Nilvebrant L, Hallen B, Larsson G. Tolterodine - a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997;60:1129-36.
19. Nilvebrant L, Glas G, Jonsson A, Sparf B. The in vitro pharmacological profile of tolterodine - a new drug for the treatment of urinary urge incontinence. Neurourol Urodyn 1994;13:433-5.
20. Brynne N, Stahl MM, Hallen B, Edlund PD, Palmer L, Hoglund P, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997;35:287-95.
21. Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs 1998;55:813-20.
22. Stahl MMS, Ekstrom B, Sparf B, Mattiasson A, Andersson KE. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995;14:647-55.
23. Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol 1998;81:42-8.
24. Van Kerrebroeck PEVA, Amarenco G, Thuroff JW, Madersbacher HG, Lock MTWT, Messelink EJ, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998;17:499-512.
25. Jonas U, Hofner K, Madersbacher H, Holmdahl TH. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor over-activity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 1997;15:144-51.
26. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-10.
27. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997;50(suppl 6A):90-6.
28. Larsson G, Hallen B, Nilvebrant L. Tolterodine in the treatment of urge incontinence. Analysis of the pooled Phase II efficacy and safety data (abstract). 26th Annual Meeting of the International Continence Society, August 27-30, 1996, Athens, Greece.
29. Malone-Lee J, Maugourd MF, Walsh B. Clinical efficacy and safety of tolterodine vs placebo in elderly patients with unstable bladder: a randomised, double-blind, multinational study (abstract). 27th Annual Meeting of the International Continence Society, September 23-26, 1997, Yokohama, Japan.
30. Moore K, Millard R, Dwyer P. A randomized controlled multicentre trial of tolterodine in detrusor instability/hyperreflexia (abstract). Int Urogynecol J Pelvic Floor Dysfunct 1997;8:S129.
31. Data on file. Pharmacia & Upjohn, Kalamazoo, MI.
32. Van Kerrebroeck PEVA, Serment G, Dreher E. Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder (abstract). Neurourol Urodyn 1997;16:478-9.
33. Drutz H, Appell RA. Clinical efficacy and safety of tolterodine vs oxybutynin and placebo in patients with unstable bladder (abstract). Acta Obstet Gynecol Scand 1997;76:24.
34. Ouslander JG, Schnelle JF. Incontinence in the nursing home. Ann Intern Med 1995;122:438-49.
35. Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment: the case of oxybutynin chloride. J Am Geriatr Soc 1998;46:8-13.
36. Peitzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994;47:337-43.
37. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
38. Bertilsson L. Geographical/interracial differences in polymorphic hepatic oxidation. Current state of knowledge of cytochrome P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
39. Marinac JS, Foxworth JW, Willsie SK. Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy black American adult subjects. Ther Drug Monit 1995;17:120-4.
40. Andersson KE. The overactive bladder: pharmacologic basis of drug treatment. Urology 1997;50(suppl 6A):74-84.
41. Ouslander JG, Schnelle JF, Uman G, Fingold S, Nigman JG, Tuico E, et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo controlled trial. J Am Geriatr Soc 1995;43:610-7.
42. Burgio KL, Lochner JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998;280: 1995-2000.
43. Wein AJ. Pharmacologic options for the overactive bladder. Urology 1998;51(suppl 2A):43-7.
44. Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing 1997;26:367-74.